The role of estrogens in Alzheimer's disease (AD) is controversial. We investigated the association between well-recognized, and potentially functional, polymorphisms in the estrogen receptor (ER) a gene and the risk of AD in a prospective study of 6056 Caucasian older men and women aged 55 years and over. In a subset of 468 participants, we assessed volumes of the hippocampus and amygdala, which have a high density of ERa, with brain magnetic resonance imaging (MRI) (1.5 T MR unit). During a total of 35 405 person-years of follow-up (mean per persons 5.8 years), 312 new cases of dementia were detected, of whom 230 were diagnosed with AD. Neither the PvuII nor the XbaI polymorphism or haplotypes thereof were associated with the risk of all-cause dementia or AD. In contrast, we found that nondemented women who carried the PvuII p allele or haplotype 'px' had smaller amygdalar volumes on MRI in an allele-dose-dependent fashion. Total amygdalar volume was 4.50 (SE 0.10) in PP genotype, 4.45 (SE 0.06) in Pp genotype, and 4.18 ml (SE 0.08) in pp genotype (P trend ¼ 0.008). Further studies are required to investigate whether this smaller amygdalar volume has functional significance.
In the last decade of the 20th century, numerous cellular, molecular, and epidemiological studies suggested a protective effect of estrogen on Alzheimer's disease (AD). Estrogen protects against neuronal death, 1 improves survival of hippocampal neurones, 2 increases dendritic spine formation, 3 and stimulates cerebral blood flow. 4 Observational studies reported that postmenopausal women who used estrogen replacement therapy have a lower risk of dementia. 5, 6 Conversely, a large randomized trial on estrogen replacement therapy for preventing AD was negative. 7 This, in turn, is in line with findings from our group that higher endogenous estradiol levels, if anything, are associated with a higher risk of dementia. 8 Estrogens exert most of their effects through intracellular activation of estrogen receptors (ERs). There are two known forms of ERs: ERa and ERb, both expressed in the brain. 9, 10 Several studies examined the PvuII and XbaI polymorphisms in the gene for ERa in association to AD with different results. [11] [12] [13] [14] [15] [16] [17] Except for one prospective study, 11 most reports were based on case-control series with inherent limitations of selection. [12] [13] [14] [15] [16] [17] The aim of the current study was to investigate polymorphisms in the ERa gene and risk of dementia in a large prospective population-based cohort study in the Netherlands.
The second objective of our study was to investigate the association between polymorphisms in the ERa gene and volumes of the hippocampus and amygdala on MRI in the medial temporal lobe. Hippocampal and amygdalar atrophy on MRI may serve as early markers of incipient AD. 18, 19 Of interest, the hippocampus and particularly the amygdala express ERa at relatively high levels, 10 suggesting that potential dysfunction of the ER could affect the morphology of these structures. If ERa polymorphisms were found to be associated with AD, one would expect a relation with these early MRI markers as well. Also, as the MRI measures are continuous outcomes, the analyses on ERa polymorphisms and brain volumes have high power to yield significant associations. However, smaller volumes of these structures are not restricted to AD and can be observed also in other disorders or be due to developmental effects.
The e4 allele of the apolipoprotein E (APOE) is a well-known genetic risk factor for AD, 20 and estrogens influence regulation of APOE synthesis. 21 Previous reports suggested differential effects of the ERa genotype on the risk of AD within APOE e4 or non-e4 carriers;
13,15 therefore we performed stratified analyses according to the APOE genotype.
Materials and methods

Study population
This study is based on the Rotterdam Study, a large prospective population-based study in 7983 elderly aged 55 years or older, which aims to assess the determinants of diseases in later life. 22 The Medical Ethics Committee of Erasmus Medical Center approved the study protocol and participants gave written informed consent. Baseline examinations took place from 1990 to 1993. A trained research assistant visited participants at home and obtained information on medication use, medical history, and determinants of diseases. Participants were invited to visit the research center for clinical examinations by the research physicians. Re-examinations were performed in 1993-1994 and 1997-1999 . Of the 7983 participants at baseline, 7528 (94.3%) were screened and examined for prevalent dementia. There were 482 participants diagnosed with prevalent dementia. 23 Thus, 7046 participants comprised the cohort at risk for dementia, of whom 6934 were of Caucasian origin.
Dementia diagnosis
Participants were examined for the presence of dementia at the research center at follow-up visits. A three-step protocol was used as described in detail elsewhere. 24 Briefly, all participants were screened with the Mini-Mental State Examination (MMSE) and the Geriatric Mental State schedule (GMS), organic level. Screen positives (persons scoring below 26 on the MMSE or more than 0 on the GMS) underwent cognitive testing with the Cambridge examination for mental disorders in the elderly, which included an informant interview. Persons suspected of dementia were examined by a neurologist and underwent extensive neuropsychological testing. In addition to this in-person screening, 25 all participants were continuously monitored for development of dementia through linkage of the general practitioners' medical record system to the database of the Rotterdam Study. We also consulted the Regional Institute for Outpatient Mental Health Care (RIAGG) at a regular basis and checked all relevant reports. Surveillance of the population through the general practitioner and RIAGG reports continued up to December 31, 1999 . A diagnosis of dementia and its subtypes was made according to international standard criteria by a panel consisting of a neurologist, neuropsychologist, and study physician. 26, 27 Subset with MRI examinations In 1995-1996, we made a random selection of 965 living members of the cohort in strata of age (5-years strata from 60 to 90) and sex for participation in the Rotterdam Scan Study, designed to study age-related brain changes on MRI. 28 As part of the eligibility criteria, we excluded persons who had developed dementia between baseline and time of selection (n ¼ 17) and persons who had contraindications to undergo MRI (n ¼ 116). This left 832 participants eligible. The MRI sequences were made using a 1.5 T MR unit (Siemens, Erlangen, Germany). Complete MRI data, including a three-dimensional (3D) volumetric MRI sequence covering the whole brain, was obtained in 511 persons.
MRI procedures
We reformatted coronal brain slices (contiguous 1.5-mm slices) and a middle sagittal slice from the 3D MRI sequence. The coronal slices were orientated perpendicular to the long axis of the hippocampus. The procedure of segmenting the hippocampus and amygdala on coronal slices has been described. 29 The left and the right hippocampus and amygdala were manually outlined on each slice with a mouse-driven cursor. Absolute volumes (ml) were calculated by multiplying the areas on each slice by the slice thickness, and left and right sides were summed. As a proxy for head size, we measured on a reformatted middle sagittal MRI slice the intracranial crosssectional area. 29 We corrected for head size differences across individuals by dividing the uncorrected volumes by the subject's calculated head size area and subsequently multiplying this ratio by the average head size area (men and women separately). 19, 30 Intraand inter-reader studies based on 14 random scans showed good reproducibility. 29 Intrarater intraclass correlation coefficients for the left and right hippocampus were r ¼ 0.93 and 0.90, and inter-rater intraclass correlation coefficients were r ¼ 0.87 and 0.83, respectively. For the left and right amygdala, the intrarater intraclass correlation coefficients were r ¼ 0.82 and 0.78, the inter-rater intraclass correlation coefficients were r ¼ 0.80 and 0.77, respectively.
ERa polymorphisms
Genomic DNA was isolated from peripheral leucocytes by standard procedures. Genotypes were determined using the Taqman allelic discrimination assay. Primer and probe sequences were optimized using the single-nucleotide polymorphism assay-by-design service of Applied Biosystems. For details, see http:// store.appliedbiosystems.com. Reactions were performed on the Taqman Prism 7900HT 384 wells format. The coding for the ERa polymorphisms PvuII and XbaI follows that of previous studies on the ERa polymorphisms. Capital 'P' and 'X' stand for absence of a restriction site (indicating respectively nucleotide C and nucleotide G) and lower case letters 'p' and 'x' stand for the presence of restriction site (nucleotides T and A). Persons were classified as either noncarrier, heterozygous or homozygous for the allele. To increase genetic resolution, we created also PvuIIXbaI haplotypes as reported previously. 31 Haplotype alleles were coded as haplotype numbers 1-4 in order of decreasing frequency in the population (1 ¼ px, 2 ¼ PX, 3 ¼ Px, and 4 ¼ pX). We examined the polymorphisms PvuII and XbaI separately in relation to outcome to make our results comparable with earlier studies on dementia, and examined haplotype 1 based on previous work from our group, showing this to be the risk allele of osteoporosis. 31 Analytical study samples We missed genotyping of the ERa polymorphism in some persons because no blood was drawn or there were problems in the technical processing of the blood samples. Of the 6934 members of the cohort at risk for dementia, we determined the
Other measurements
At baseline examinations, we ascertained by interview or physical examination the level of education (primary vs lower vocational to university education), smoking status (current, former or never), body mass index (weight divided by the square of the height), age at menopause (either natural or surgically induced), 32 and use of estrogen replacement therapy (ever vs never). Plasma total estradiol levels were available in 960 participants of the total cohort. 8 APOE genotype was determined in 5281 participants of the total cohort and in 404 participants of the subset with MRI examination. 33 We classified participants into those with or without the e4 allele.
Data analysis
Analyses were performed separately in men and women. We compared baseline characteristics in ERa genotype using one-way analysis of variance or w 2 analysis in the total study cohort. The hazard ratios of dementia and AD were estimated using a Cox proportional hazard model in which time scale is the age of participants. Left truncation of the cohort was accounted for by using the 'counting process' notation available in S-Plus. 34 In the subset with MRI examinations, we used analysis of covariance to compute age-adjusted means of the brain volumes on MRI within genotype. As preliminary analyses did not suggest a dominant or recessive effect of the polymorphisms, we analyzed the association using an allele-dose model. The genotype was entered as a linear term in the model to yield P-values of the allele-dose trend. Besides age, we additionally included the following confounders in the analyses that have previously been associated to dementia: level of education, 23 body mass index, 35 smoking, 36 age at menopause, 37 and ever use of estrogen replacement therapy. 38 
Results
Allele frequencies of the ERa polymorphisms were in Hardy-Weinberg equilibrium and similar to frequencies found in other Caucasian populations (Table  1) . 39, 40 In the total cohort, the mean age at baseline was 69.0 years (SD 8.7), mean body mass index was 26.4 (SD 4.0), and mean MMSE was 27.6 (SD 1.9). In ERa, dementia, and brain MRI T den Heijer et al all, 37% had followed primary education only, 23% currently smoked, and 10% had ever used hormone replacement therapy. We found no significant differences in age, educational level, smoking, body mass index or ever use of hormone replacement therapy across genotype. In 960 participants (441 men and 519 women), plasma total estradiol levels were available. 8 Women with the xx or Xx genotype had slightly lower estradiol levels compared to women with the XX genotype (XX 19.6 pmol/l, Xx 15.1 pmol/l (P ¼ 0.02), xx 15.4 pmol/l (P ¼ 0.04)). Women with the pp genotype had a 0.5 years later age of menopause compared to women with the PP genotype (P ¼ 0.03), which confirms our previous report in a smaller part of the cohort. 32 The MMSE scores at baseline were similar across genotype. After baseline, during 35 405 person-years of follow-up (mean per person 5.8 years), 312 participants developed dementia. A diagnosis of probable AD was made in 230 participants. We found no association between ERa polymorphisms and the risk of all-cause dementia or AD, either in men or women (Table 2) . Additional adjustments for educational level, smoking, body mass index, age at menopause, and use of estrogen replacement therapy did not change our findings. There was also no association between the ERa polymorphisms and dementia when we separately looked within APOE non-e4 carriers or e4 carriers (data not shown).
In the subset with MRI examinations (n ¼ 468), we found smaller hippocampal and amygdalar volumes on MRI in women with the pp or xx genotype compared to women with the PP or XX genotype (Table 3) . There was an allele-dose effect: per allele copy of the 'p' allele the amygdala was À0.17 ml smaller (95% CI À0.30 to À0.05) and per allele copy of the 'x' allele À0.17 ml (95% CI À0.30 to À0.04). The explained variance in amygdalar volume by the PvuII polymorphism above age was 3% (R 2 change 0.030, F(1,221) ¼ 7.11, P ¼ 0.008). There were 25 cases of incident dementia in the subset with MRI, and excluding them did not change the results. There was no association between the ERa polymorphism and brain volumes in men. Additional adjustments for educational level, smoking, body mass index, age at menopause, and use of estrogen replacement therapy did not change the results. There was no difference in the results when we stratified by APOE genotype.
The haplotype 1 (px) genotype followed exactly the PvuII genotype and therefore the analyses on haplotype 1 in association with outcome were similar as we report for the PvuII polymorphism.
Discussion
In this report based on a large population-based study, we show no effect of the PvuII and XbaI polymorphisms in the ERa gene on the risk of dementia. However, we observed women with the p or x allele or haplotypes thereof to have smaller amygdalar volumes on MRI compared with women with the P or X allele. There was no differential effect according to APOE genotype.
The potential dangers of genetic association studies are population stratification or heterogeneity. This particularly holds for case-control studies in persons of mixed racial origin. In our study, this has played no role since all subjects were of Dutch Caucasian origin and can be considered ethnically homogeneous. Furthermore, allele frequencies were similar to those found in studies of other Caucasian subjects. 40 Our Table 2 PvuII and XbaI ERa polymorphism and risk of incident dementia and AD in the total sample (n ¼ 6056) 41 a proinflammatory phenotype of microglia localized in the hippocampus and amygdala, 42 and abolishment of the protective effect of estradiol on ischemic brain injury. 43 Furthermore, brains of patients with AD have less hippocampal neurons stained with ERa, indicating a potential role of dysfunctional ERa in the pathogenesis of AD. 44 The PvuII-XbaI polymorphisms in the ERa gene are attractive polymorphisms to investigate in association to AD, as they have been implicated in estrogenrelated diseases such as osteoporosis, 31 heart disease, 45 and breast cancer. 46 Also, we showed that women carrying the px haplotype were shorter, 47 and have a later age of menopause in the current sample extending our previous sample. 32 Given that the PvuII and XbaI polymorphisms are in strong linkage disequilibrium, 31 it is difficult to determine which of the two polymorphic sites is driving the associations. Both of them have an intronic localization and functional consequences on a biochemical level have still not been established. Interestingly though, Herrington et al 48 recently showed that the T-allele of the PvuII polymorphism-corresponding to the 'p' allele in our analyses-lacks a binding site for the transcription factor bMyb, which might result in lower ERa transcription. Nuclear ERa receptors bind to estrogen response elements in promotor regions of target genes, which in turn stimulate expression of genes thought to be involved in neuroprotection. 49 Therefore, neurons expressing low ERa may be posed vulnerable to toxic events. Our findings did not support the hypothesis that ERa PvuII-XbaI genotypes are associated with vulnerability to AD. We did find the ERa PvuII-XbaI genotype to be associated with amygdalar volume in women. This could be a false-positive finding. However, the population-based design, the size of the sample, and the allele-dose effect of the relation support a true association. Furthermore, genotype effects were similar, although weaker, for the hippocampus. This is in striking similarity with the higher density of ERa in the amygdala compared to the hippocampus. 10, 50 Although amygdalar atrophy is found in early AD 19 , exclusion of people who developed AD during follow-up did not change the results. This limits the possibility that early AD accounted for the findings on the amygdala. Does this smaller amygdalar volume then have any functional significance? The amygdala has several functions in emotional behavior and fear conditioning, and a smaller amygdala is reported in anxiety disorders. [51] [52] [53] [54] One may speculate that a smaller amygdala is the structural link between recently reported associations of polymorphisms in the ERa gene and anxiety. 51, 52, 55 Future studies should include both amygdala volume and psychometric assessments of anxiety to test this hypothesis. 
